PEABODY, Mass., October 22, 2021 --Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining their lead asset PRV111 in subjects with early-stage Head and Neck Squamous Cell Carcinoma (HNSCC). PRV111 is an innovative transmucosal delivery...
Peabody, MA -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on patients”, announced today that the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health...
PEABODY, Mass., June 3, 2021 -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on patients”, announced today a poster presentation on the safety and efficacy of PRV111 in patients with...
PEABODY, Mass., Sept. 24, 2020 -- Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal cancers, announced today that Privo and its CEO, Manijeh Goldberg, Ph.D., have been selected as the winner of the 2020...
Privo Technologies, Inc. attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year due to COVID-19, Bio International 2021 was informative and enjoyable. The company connected with potential investors and industry partners in discussing their...
Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment of Dr. James Mackay to Its Board of Directors. BOSTON, June 30, 2020 (Newswire.com) - Dr. Mackay joins the Board of Directors...
The Salisbury Award Competition is a set of competitions participated in by investigators at major cancer research institutions and/or scientists at promising early stage companies. Winners and runners-up receive cash prizes based on their presented cancer therapy concepts, breakthroughs, discoveries or...
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit.
Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD) Grant program to further support the Phase II clinical study. Privo Technologies is one of 12 institutions in the US...
Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute (NIDCR) in Philadelphia.
- © UX Strategy & Digital Branding